TOP-5 Analyst Price Targets as of October 16, 2025

Revolution Medicines [US76155X1000] Stifel has resumed coverage with a "Buy" rating and a price target of $85 (70% upside potential) Analysts see the company on the verge of fundamentally changing the treatment standard for pancreatic ductal adenocarcinoma (PDAC). The development of a pan-RAS therapy is particularly highlighted, which is considered "First-in-Class” and could potentially be used in approximately 30% of all solid tumors. The addressable market is described as "huge,” and Stifel predicts that Revolution will generate...